Trials
Search / Trial NCT00001280

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of January 13, 2025

Completed

Keywords

Aspergillosis Phagocyte Defect Torulopsis Chronic Granulomatous Disease

ClinConnect Summary

This protocol describes a prospective, randomized study examining the safety and efficacy of Itraconazole for preventing fungal infections in patients with Chronic Granulomatous Disease (CGD). CGD is a genetic disorder in which phagocytes are unable to produce oxygen radicals. As a result, affected patients are prone to recurrent, severe infections with bacterial and fungal organisms. Patients with CGD of 5 or more years of age without evidence of infection at the time of study entry will be eligible for enrollment. Patients will be randomized to receive itraconazole or placebo tablets dail...

Gender

ALL

Eligibility criteria

  • • Documented chronic granulomatous disease more than 5 years of age.
  • • No fungal infection within the past year.
  • • Not currently on other antifungals or have taken other antifungals during the past 3 months.
  • • Not currently on phenytoin or rifampin.
  • • Negative pregnancy test within 2 weeks of starting protocol.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials